Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company's website at www.sutrobio.com. Archived replays will be available for ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

Along with PCI's own robust infrastructure expansions, acquisition furthers CDMO's recent growth in sterile fill-finish, advanced drug delivery ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The drug will be marketed under the brand name Imaavy.